Arrowhead Pharmaceuticals, Inc.
Conduct independent commercial launch of plozasiran
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 18 Nov 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans for an independent commercial launch in 2025”
What we found
Evidence strength A What the grades mean
FDA approved REDEMPLO (plozasiran) on November 18, 2025; Arrowhead stated it would be commercially available in the US before year-end, confirmed in its FY2025 10-K as its first commercial launch.
-
A Arrowhead Pharmaceuticals, Inc. - Form 10-K - FY2025 10-K confirms FDA approval Nov 18, 2025 and describes it as first commercial launch in 2025
-
A Arrowhead Pharmaceuticals, Inc. - Form 424B5 - FY2026 SEC filing states Arrowhead 'achieved a transformational milestone with its first commercial launch in 2025'
-
B Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran)... FDA approval announced; company states drug available in US before end of 2025
-
C Arrowhead strikes true with 1st FDA approval, but Ionis competition looms News coverage confirms Arrowhead's independent commercial launch via FDA approval
Checked 16 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Conduct
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Arrowhead Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ARWR-000411 · Corrections policy